Bimekizumab (Bimelex), a dual IL-17A/F inhibitor, is FDA approved for u Treatment of Adults with Moderate to Severe Plaq
Tweet Content
Bimekizumab (Bimelex), a dual IL-17A/F inhibitor, is FDA approved for u Treatment of Adults with Moderate to Severe Plaque Psoriasis https://t.co/IeobNWcM94 https://t.co/OMbhVwFCCt
Show on Archive Page
On
Display in Search Results
On
PDQ
Off